10.1021/acsmedchemlett.9b00534.s001 Eric M. Gordon Eric M. Gordon Matthew A. J. Duncton Matthew A. J. Duncton Brian J. Wang Brian J. Wang Longwu Qi Longwu Qi Dazhong Fan Dazhong Fan Xianfeng Li Xianfeng Li Zhi-Jie Ni Zhi-Jie Ni Pingyu Ding Pingyu Ding Ruslan Grygorash Ruslan Grygorash Eddy Low Eddy Low Guijun Yu Guijun Yu Jiawei Sun Jiawei Sun Toward Orally Absorbed Prodrugs of the Antibiotic Aztreonam. Design of Novel Prodrugs of Sulfate Containing Drugs. Part 2 American Chemical Society 2020 FDA Gram-negative bacteria Part 2 Aztreonam monocyclic beta-lactam antibiotic aztreonam Novel Prodrugs Sulfate Containing Drugs Antibiotic Aztreonam 2020-01-10 14:39:35 Journal contribution https://acs.figshare.com/articles/journal_contribution/Toward_Orally_Absorbed_Prodrugs_of_the_Antibiotic_Aztreonam_Design_of_Novel_Prodrugs_of_Sulfate_Containing_Drugs_Part_2/11568711 Aztreonam, first discovered in 1980, is an FDA approved, intravenous, monocyclic beta-lactam antibiotic. Aztreonam is active against Gram-negative bacteria and is still used today. The oral bioavailability of aztreonam in humans is less than 1%. Herein we describe the design and synthesis of potential oral prodrugs of aztreonam.